- Association between HLA-B*1301 and dapsone-induced cutaneous adverse drug reactions: A systematic review and meta-analysis
- Similar efficacy and safety of Basaglar and Lantus in patients with type 2 diabetes in age groups (< 65 years, ≥ 65 years): A post hoc analysis from the ELEMENT-2 Study
- Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A phase III, multicenter, randomized trial (SUMIT)
- Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaxime-resistant Enterobacteriaceae bacteremia
- Randomized, double-blind, placebo-controlled, multicenter phase II study of fruquintinib after two prior chemotherapy regimens in Chinese patients with advanced nonsquamous non-small-cell lung cancer
- Efficacy of curcumin and boswellia for knee osteoarthritis: Systematic review and meta-analysis
- Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study
- A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC)
- Associations of early opioid use with patient-reported outcomes and health care utilization among older adults with low back pain
- Effect on cerebral oxygenation of paracetamol for patent ductus arteriosus in preterm infants
- A randomized, double blind, controlled, multi center study of Ilaparazole in the treatment of reflux esophagitis – Phase III clinical trial
- A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: Final results of the INPACT trial
- Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation
- Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin vs standard therapy for relapsed/refractory acute lymphoblastic leukemia
- A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD
Feed Sources
